FDA Approves Merck’s Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection, in Combination with Other Antiemetic Agents, for the Prevention of Delayed Nausea and Vomiting in Adults Receiving Moderately Emetogenic Chemotherapy (MEC)
Dateline City:
KENILWORTH, N.J.
First and Only Intravenous NK1 Receptor Antagonist Approved in the U.S. for Use in MEC
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
approved a supplemental new drug application (sNDA) for single-dose EMEND®
(fosaprepitant dimeglumine) for injection, Merck’s substance
P/neurokinin-1 (NK1) receptor antagonist, in combination with
other antiemetic medicines, for the prevention of delayed nausea and
vomiting in adults receiving initial and repeat courses of moderately
emetogenic chemotherapy (MEC).
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558An Phan, 908-255-6325orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK Emend MSD Source Type: news
More News: Chemotherapy | Food and Drug Administration (FDA) | Merck | Neurology | New Drug Applications | Pharmaceuticals